Atara Biotherapeutics appoints Ameet Mallik to Board of Directors

Atara Biotherapeutics, Inc.

Ameet Mallik appointed to fill vacant Board seat effective August 9, 2021.
Initial term expires at 2024 annual meeting; no standing committee assignments.
Mr. Mallik determined independent under SEC and Nasdaq listing standards.
Receives annual retainer of $45,000 (pro-rated) and option for 55,000 shares vesting over 3 years.
Standard indemnification agreement entered into with the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ameet Mallik

Director

ATRA · Atara Biotherapeutics, Inc.

Effective: 2021-08-09
Filed: August 10, 2021, 7:59 PM ET

On August 9, 2021 (the “Effective Date”), the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc. (the “Company”) appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, Ameet Mallik to fill the vacant Board seat and to serve as a member with an initial term expiring at the Company’s 2024 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ameet Mallik was appointed as Director at Atara Biotherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 9, 2021 (the “Effective Date”), the Board of Directors (the “Board”) of Atara Biotherapeutics, Inc. (the “Company”) appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, Ameet Mallik to fill the vacant Board seat and to serve as a member with an initial term expiring at the Company’s 2024 annual meeting of stockholders.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-241776

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.